IL17A and neoplasm: In contrast, ILC3 have also been found to promote tumor progression via secretion of high levels of IL-17 and IL-22 (47–49), which in turn have been related in solid tumors with metastatic progression, tumor growth (47, 48), and chemoresistance (49), respectively.